Dompé México

Dompé is a global biopharmaceutical company headquartered in Italy with a dedicated subsidiary in Mexico. The company specializes in the development and commercialization of innovative therapies for rare diseases, ophthalmology, and oncology. Its lead product, Oxervate (cenegermin), represents a breakthrough as the first recombinant human nerve growth factor approved for neurotrophic keratitis. Dompé México serves as a strategic hub for expanding access to these specialized treatments across the Latin American region. The company maintains a robust R&D pipeline focused on modulating inflammatory and regenerative pathways to address significant unmet medical needs.